Chinese
English
Home
Gan & Lee Overview
Company Profile
Company Culture
Marketing Network
Member Companies
Strategic Partners
Gan & Lee History
Contact Us
Newsroom
Media Focus
Company News
Industry News
Honors and Awards
International Business
Products
Insulin Analogue
Medical Devices
R&D
Intellectual Property
Social Responsibility
Diabetes and Insulin
Careers
Why choose Gan & Lee
What we are looking for
What we can offer
Join us
GDPR POLICY
GDPR FOR CHINA
GDPR FOR USA
Newsroom
Media Focus
Company News
Industry News
Honors and Awards
International Business
Fast Track
Company News
Home
Newsroom
Company News
2020-11-09
BASALIN® (GLARGINE) of GAN & LEE PHARMACEUTICALS WAS APPROVED in KAZAKHSTAN
2020-10-10
Jiangsu Gangan —A Subsidiary of Gan & Lee Receives FDA Clearance for Insulin Injection Pen Needle
2020-09-11
Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Orphan Drug Designation by the US FDA
2020-07-31
Gan & Lee Pharmaceuticals Initiates First-in Human Phase 1 Clinical Trial for New Anti-tumor Drug GLR2007
2020-06-30
New Journey of Listed Gan & Lee
2020-06-10
Listed China's 1st Insulin Aspart Injection from Gan & Lee Pharmaceuticals
<<
1
2
3
4
5
>>
